We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

118 hedge funds and large institutions have $91.5M invested in Sanofi Contingent Value Rights in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $59.7M → $91.5M (+$31.8M)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 118118 (0)

62% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 34

Holders
118
Holders Change
Holders Change %
0%
% of All Funds
3.15%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
15
Increased
13
Reduced
34
Closed
14
Calls
Puts
Net Calls
Net Calls Change

GCVRZ Hedge Fund Activity: Q4 2014 in Review

118 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2014, worth a combined $91.5M — up 53% from $59.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GCVRZ positions and 14 closed out — a net gain of 1 holder — while 13 added to existing stakes and 34 trimmed.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.4M. The largest seller was Gruss Capital Management, cutting an estimated $3.02M.

  • 118 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $91.5M of Sanofi Contingent Value Rights stock for Q4 2014, up 53% quarter-over-quarter.
  • 15 funds opened new Sanofi Contingent Value Rights positions in Q4 2014 and 14 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2014 was Oxford Asset Management, an estimated $2.4M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2014 was Gruss Capital Management, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2014.